Cassava Sciences SAVA shares are trading higher Tuesday after the company announced results of an interim analysis from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease.
"Patients' cognition and behavior scores both improved following six months of simufilam treatment, with no safety issues," according to the company.
Cassava Sciences is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. It's also developing an experimental biomarker diagnostic PTI-125 to detect Alzheimer's disease with the help of a blood test.
Cassava Sciences shares traded up 150% at $57.66 at the time of publication. The stock has a 52-week high of $74.50 and a 52-week low of $1.63.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
